Cardiovascular effects and mechanisms of sodium-glucose cotransporter-2 inhibitors.
Fan Yang,Ran Meng,Da-Long Zhu +2 more
Reads0
Chats0
TLDR
Three aspects of SGLT2 inhibitors are summarized: the recent clinical evidence of their cardiovascular benefits, their mechanisms of action, and their safety.About:
This article is published in Chronic Diseases and Translational Medicine.The article was published on 2020-08-15 and is currently open access. It has received 4 citations till now. The article focuses on the topics: Kidney disease & Type 2 diabetes.read more
Citations
More filters
Journal ArticleDOI
Sodium-Glucose Cotransporter Type 2 Inhibitors and Cardiac Arrhythmias.
TL;DR: The antiarrhythmic mechanisms involved include reverse atrial and ventricular remodeling, amelioration of mitochondrial function, reduction of hypoglycemic episodes with their attendant arrhythmogenic effects, attenuated sympathetic nervous system activity, regulation of sodium and calcium homeostasis, and suppression of prolonged ventricular repolarization as discussed by the authors .
Journal ArticleDOI
Empagliflozin Alleviates Left Ventricle Hypertrophy in High-Fat-Fed Mice by Modulating Renin Angiotensin Pathway
Juliana C. Cotrin,Gabriel Santos Martins de Souza,Tamiris Ingrid Petito-da-Silva,Luiz E.M. Cardoso,Vanessa Souza-Mello,Sandra Barbosa-da-Silva +5 more
TL;DR: The results suggests that empagliflozin modulates the local RAS pathway towards alleviation of oxidative stress and ER stress in the LV, which may be a route to its effects on improved cardiac remodeling.
Journal ArticleDOI
Sex differences in cardiovascular outcomes of SGLT-2 inhibitors in heart failure randomized controlled trials: A systematic review and meta-analysis
F. B. Rivera,V. Tang,D. D. De Luna,Edgar V. Lerma,Krishnaswami Vijayaraghavan,Amir Kazory,Nilay Shah,Annabelle Santos Volgman +7 more
TL;DR: In this article , the authors explored potential sex differences in primary composite outcomes among patients with heart failure treated with SGLT-2is and found that the primary composite outcome was significantly lower in females compared with males.
Journal ArticleDOI
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
TL;DR: In this article , the authors focus on the possible effects of SGLT2 inhibitors on different body systems, including brain function, synaptic plasticity, acetylcholinesterase activity, and reduce amyloid plaque formation, as well as regulation of the mTOR pathway in the brain.
References
More filters
Journal ArticleDOI
Comparative efficacy of once-weekly semaglutide and SGLT-2 inhibitors in type 2 diabetic patients inadequately controlled with metformin monotherapy: a systematic literature review and network meta-analysis.
Rohini Sharma,Lars Wilkinson,Hrvoje Vrazic,Evan Popoff,Sandra Lopes,Steve Kanters,Eric Druyts +6 more
TL;DR: Once-weekly semaglutide treatment is significantly better compared to SGLT-2is in achieving adequate glycemic control in T2D patients inadequately controlled with metformin monotherapy.
Journal ArticleDOI
Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials
R. Devi,Ghanshyam Mali,Indrani Chakraborty,Mazhuvancherry Kesavan Unnikrishnan,Suhaj Abdulsalim +4 more
TL;DR: This meta-analysis shows empagliflozin is safe and effective for the treatment of T2DM along with existing diabetes pharmacotherapy.
Journal ArticleDOI
Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
José Luis Górriz,Juan F. Navarro-González,Alberto Ortiz,Ander Vergara,Julio Núñez,Conxita Jacobs-Cachá,Alberto Martínez-Castelao,María José Soler +7 more
TL;DR: Clinical experience suggests that SGLT2i safety management may in part mirror renin–angiotensin blockade safety management in patients with overt DKD, and proposed clinical steps for maximizing the safety of SGLt2i in DKD patients on other antidiabetic, BP or diuretic medication are proposed.
Journal ArticleDOI
Reduction in HbA1c with SGLT2 inhibitors vs. DPP-4 inhibitors as add-ons to metformin monotherapy according to baseline HbA1c: A systematic review of randomized controlled trials
TL;DR: Because of the small difference in Δ HbA1c whatever the baseline Hb a1c level with SGLT2is vs DPP-4is as add-ons to metformin, choosing between these glucose-lowering agents in clinical practice should be based on other efficacy criteria or on safety profiles rather than on Hba1c levels.
Book ChapterDOI
GLP-1 Receptor Agonists and SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: New Insights and Opportunities for Cardiovascular Protection.
TL;DR: The fundamental results of the clinical trials on SGLT2i and GLP-1RA, their clinical relevance in term of treatment of T2D, and the mechanisms that may explain how these drugs exert their cardiovascular protective effects are examined.